{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T03:13:56Z","timestamp":1787973236768,"version":"build-2784847793"},"reference-count":33,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"unspecified","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"F. Hoffmann\u2013La Roche Ltd","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,5,22]]},"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The combination of checkpoint inhibition and cisplatin-based chemotherapy is investigated in muscle invasive bladder cancer (MIBC) and results from phase 2 trials have been presented. Intravesical BCG has been used for non-MIBC (NMIBC) in patients with carcinoma in situ and high-grade Ta\/T1 tumours. BCG induces innate and adapted immune response and upregulation of PD-L1 in preclinical models. The proposed trial is intended to implement a new immuno-immuno-chemotherapy induction therapy for MIBC. The combination of BCG and checkpoint inhibition with chemotherapy aims at higher intravesical responses and better local and systemic control of disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>SAKK 06\/19 is an open-label single-arm phase II trial for patients with resectable MIBC T2-T4a cN0-1. Intravesical recombinant BCG (rBCG: VPM1002BC) is applied weekly for three instillations followed by four cycles of neoadjuvant cisplatin\/gemcitabine every 3 weeks. Atezolizumab 1200\u2009mg every 3 weeks is started together with rBCG and given for four cycles. All patients then undergo restaging and radical cystectomy and pelvic lymphadenectomy. Atezolizumab is continued as maintenance therapy after surgery every 3 weeks for 13 cycles. Pathological complete remission is the primary endpoint. Secondary endpoints include pathological response rate (&lt;ypT2\u2009N0), event-free survival, recurrence-free survival, overall survival, feasibility and toxicity. An interim safety analysis will be performed after the first 12 patients have completed neoadjuvant treatment specifically assessing toxicity possibly associated with intravesical rBCG application.<\/jats:p>\n                    <jats:p>The study has received approval by ethical committee Zurich, Switzerland, BASEC-No. 2021\u201301872. Results will be made available by publication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04630730\">NCT04630730<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-067634","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T12:43:07Z","timestamp":1686141787000},"page":"e067634","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy \u2013 protocol of a multicentre, single arm phase 2 trial (SAKK 06\/19)"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04630730","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3412-2009","authenticated-orcid":false,"given":"Ulf","family":"Petrausch","sequence":"first","affiliation":[{"name":"OnkoZentrum, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Spahn","sequence":"additional","affiliation":[{"name":"Lindenhof Group, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Schneider","sequence":"additional","affiliation":[{"name":"Competence Center, SAKK, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2265-6559","authenticated-orcid":false,"given":"Stefanie","family":"Hayoz","sequence":"additional","affiliation":[{"name":"Competence Center, SAKK, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrill A","family":"Rentsch","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Rothschild","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cantonal Hospital, Baden, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelius","family":"Omlin","sequence":"additional","affiliation":[{"name":"OnkoZentrum, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Cathomas","sequence":"additional","affiliation":[{"name":"Division of Oncology\/Hematology, Cantonal Hospital Graub\u00fcnden, Chur, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"2025121422444711000_13.6.e067634.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.03.055"},{"key":"2025121422444711000_13.6.e067634.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022148"},{"key":"2025121422444711000_13.6.e067634.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.3139"},{"key":"2025121422444711000_13.6.e067634.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.04.006"},{"key":"2025121422444711000_13.6.e067634.5","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.21.02051","article-title":"Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or Gemcitabine and cisplatin as perioperative chemotherapy for patients with Nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial","volume":"40","author":"Pfister","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025121422444711000_13.6.e067634.6","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1200\/JCO.2021.39.15_suppl.4503","article-title":"Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257","volume":"39","author":"Galsky","year":"2021","journal-title":"JCO"},{"key":"2025121422444711000_13.6.e067634.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683"},{"key":"2025121422444711000_13.6.e067634.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01148"},{"key":"2025121422444711000_13.6.e067634.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0628-7"},{"key":"2025121422444711000_13.6.e067634.10","doi-asserted-by":"publisher","DOI":"10.1038\/nature13904"},{"key":"2025121422444711000_13.6.e067634.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00561-4"},{"key":"2025121422444711000_13.6.e067634.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33297-X"},{"key":"2025121422444711000_13.6.e067634.13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eururo.2019.03.015","article-title":"Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract","volume":"76","author":"Sternberg","year":"2019","journal-title":"European Urology"},{"key":"2025121422444711000_13.6.e067634.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32455-2"},{"key":"2025121422444711000_13.6.e067634.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30230-0"},{"key":"2025121422444711000_13.6.e067634.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.08.016"},{"key":"2025121422444711000_13.6.e067634.17","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.1995.13.6.1404","article-title":"Oettgen HF: intravesical Bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial","volume":"13","author":"Herr","year":"1995","journal-title":"J Clin Oncol"},{"key":"2025121422444711000_13.6.e067634.18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG Immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol"},{"key":"2025121422444711000_13.6.e067634.19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci Transl Med"},{"key":"2025121422444711000_13.6.e067634.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.02.061"},{"key":"2025121422444711000_13.6.e067634.21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24617"},{"key":"2025121422444711000_13.6.e067634.22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01147"},{"key":"2025121422444711000_13.6.e067634.23","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1748981","article-title":"Results of the phase I open label clinical trial SAKK 06\/14 assessing safety of intravesical instillation of Vpm1002Bc, a recombinant mycobacterium Bacillus Calmette Guerin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy","volume":"9","author":"Rentsch","year":"2020","journal-title":"Oncoimmunology"},{"key":"2025121422444711000_13.6.e067634.24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.euo.2021.12.006","article-title":"A phase 1\/2 single-arm clinical trial of recombinant Bacillus Calmette-Gu\u00e9rin (BCG) Vpm1002Bc immunotherapy in non-muscle-invasive bladder cancer recurrence after conventional BCG therapy: SAKK 06\/14","volume":"5","author":"Rentsch","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"2025121422444711000_13.6.e067634.25","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24914"},{"key":"2025121422444711000_13.6.e067634.26","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1200\/JCO.2022.40.16_suppl.4515","article-title":"Perioperative chemoimmunotherapy with durvalumab for operable muscle-invasive urothelial carcinoma (MIUC): primary analysis of the single arm phase II trial SAKK 06\/17","volume":"40","author":"Cathomas","year":"2022","journal-title":"JCO"},{"key":"2025121422444711000_13.6.e067634.27","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-016-1037-z","article-title":"Gemcitabine reduces MDSCs, Tregs and TGFbeta-1 while restoring the Teff\/Treg ratio in patients with pancreatic cancer","volume":"14","author":"Eriksson","year":"2016","journal-title":"J Transl Med"},{"key":"2025121422444711000_13.6.e067634.28","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22588"},{"key":"2025121422444711000_13.6.e067634.29","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.21.01485","article-title":"Neoadjuvant Atezolizumab with Gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm","volume":"40","author":"Funt","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025121422444711000_13.6.e067634.30","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.21.01003","article-title":"Phase II study of Gemcitabine and split-dose cisplatin plus Pembrolizumab as Neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer","volume":"39","author":"Rose","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025121422444711000_13.6.e067634.31","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical Immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci Transl Med"},{"key":"2025121422444711000_13.6.e067634.32","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1999.00756.x"},{"key":"2025121422444711000_13.6.e067634.33","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.euo.2021.11.002","article-title":"Somatic features of response and relapse in non-muscle-invasive bladder cancer treated with Bacillus Calmette-Gu\u00e9rin Immunotherapy","volume":"5","author":"Bacon","year":"2022","journal-title":"Eur Urol Oncol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-067634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:44:56Z","timestamp":1765781096000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-067634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,7]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1136\/bmjopen-2022-067634"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-067634","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}